TRXBTRex Bio, Inc.
临床阶段生物制药公司,开发调节免疫平衡、促进组织修复的药物。
$14发行价
$116M融资额
$14首日收盘
0.00%首日表现
临床阶段生物制药公司,开发调节免疫平衡、促进组织修复的药物。
公司简介(来源:StockAnalysis)
TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines. It develops medicines that helps restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. The company’s product pipeline focuses on augmenting tissue Tregs to address critical treatment gaps and offers TRB-061, a phase 1 trial TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balanc...
51CFO 判断:需精通免疫学管线估值建模、早期临床数据货币化叙事及autoimmune领域投资者沟通。
管理层与创始团队详情以 SEC 招股书披露为准
你的公司需要这样的 CFO 吗?
51CFO 是专注美股市场的投行团队:赴美 IPO、借壳上市、壳公司买卖、SPAC 与 De-SPAC、SEC 申报与上市后再融资,从架构到敲钟一条龙操盘。免费 30 分钟上市路径诊断,24 小时内回复。
预约咨询